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Abstract 
We present for consideration a hypothesis that impaired movement of lipoprotein particles in the extracellular 
space in the brain in ageing is central to and causes all the key pathophysiological features of Alzheimer’s disease 
(AD). The role of lipoprotein particles is to transport cholesterol from glial cells, where it is synthesised, to neu-
rons, which require cholesterol for synaptic plasticity. The lipoprotein particles have a cholesterol-containing 
hydrophobic core, in which amyloid-β (Aβ) can be solubilised. The core is surrounded by a hydrophilic surface 
containing apolipoprotein E (APOE) which, as neurons bear receptors for APOE, determines the destination of 
the particles. The problem arises because the extracellular space is a narrow cleft, barely wider than the lipopro-
tein particles themselves, which they have to navigate in order to perform their crucial cholesterol-transporting 
function. We explain how lipoprotein particles could become trapped in the ageing extracellular matrix and that 
this primary abnormality results in reduced delivery of cholesterol to neurons leading to impaired synaptic plas-
ticity, crucial for learning and memory. It can also explain extracellular Aβ accumulation, to which a microglial 
response generates a neurotoxic reaction, and intraneuronal tau aggregation, each of which exacerbate the 
problem. All these players have been known for many years to be important in Alzheimer’s pathogenesis but a 
single unifying mechanism to explain how they are linked has been lacking. This proposed mechanism, with en-
trapment of lipoproteins particles as key to the development of AD, can explain the failure of so many clinical 
trials and points out new directions to be taken. 
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Genetics shows the overriding 
importance of apolipoprotein E 
In a complex multifaceted disease process, 
such as Alzheimer’s disease (AD), genetic factors are 
important in highlighting key elements relevant to 
the onset of the disease. By far the major genetic risk 
factor for AD, in terms of scale of effect, is the 
apolipoprotein E genotype (gene: APOE, protein: 
APOE). There are 3 common APOE gene alleles (ε2, 
ε3 and ε4); as each person inherits one allele from 
either parent there is a total of 6 APOE genotypes 
(ε2/ε2, ε2/ε3, ε3/ε3, ε3/ε4 and ε4/ε4). The APOE ε4 
allele carriage rate (i.e. the proportion of people in a 
population who possess one or two ε4 alleles) is typ-
ically about 25% of people of European ancestry [1], 
but varies considerably around the world among dif-
ferent populations [2]. A single copy of the APOE ε4 
allele confers a two to fourfold increased risk of de-
veloping AD, with ε4 homozygotes at fourteen times 
increased risk of developing AD, whereas the less 
common ε2 allele confers relative protection, ap-
proximately halving the risk [3]. The effect is so sub-
stantial that a person who is ε4 homozygous and 
lives to 85 years of age has a lifetime risk of AD of 
more than 50%, comparable to the risk associated 
with BRCA1 mutation in breast cancer [4]. On the 
other hand, the protective effect of APOE ε2 is so 
substantial that ε2 homozygotes have a very low 
likelihood of developing AD; ε2 homozygotes have a 
87% lower odds ratio than ε3 homozygotes and a 
99.6% lower odds ratio than ε4 homozygotes [5]. 
The APOE gene polymorphism is lacking from non-
human primates [6, 7] although, interestingly, Rhe-
sus monkeys which have an ε4-like APOE sequence 
develop Aβ plaques as they age [8]. The fact that 
there are more than 200 animal models of AD high-
lights the difficulty in mimicking the complexity of 
the human disease in experimental animals. A com-
plete understanding of the pathophysiology of AD 
ideally would explain all aspects of the human dis-
ease, and in particular incorporate the role of the 
APOE protein; how it causes and interacts with the 
accumulation of amyloid-β (Aβ) and tau proteins, 
the glial cell activity and most importantly, the neu-
ronal and synaptic dysfunction and loss. 
The function of APOE is to deliver 
cholesterol, packaged in lipoprotein 
particles, to neurons 
APOE is the principal cholesterol carrier in the 
brain, acting as a detergent with hydrophobic and 
hydrophilic moieties. Its main role is to solubilise 
cholesterol and other lipids and lipid-soluble sub-
stances to enable them to be transported in the 
aqueous extracellular environment of the brain. The 
importance of cholesterol to the brain is highlighted 
by the fact that 25% of the body’s cholesterol is con-
tained within the brain, despite the brain represent-
ing only 2% of the body weight [9]. Cholesterol 
forms about 30% of the lipid bilayer of the mem-
brane of all cells and is important in maintaining 
membrane fluidity. In the brain, the cell membrane 
is essential for conducting the action potential and 
for communication between neurons at synapses. 
However, despite its importance to neuronal func-
tion, neurons do not synthesise their own choles-
terol, but rely on cholesterol which is synthesised by 
glial cells and then transported to neurons [10]. De-
livery of cholesterol to neurons is in particular de-
mand when the neuron changes, as in synaptic plas-
ticity which underpins learning and memory which 
are particularly affected in AD [11]. Of note, ge-
nome-wide association studies have highlighted pol-
ymorphisms in genes in addition to APOE that are 
involved in cholesterol handling (CLU, PICALM, BIN1 
and ABCA7) as risk factors for AD [12, 13], support-
ing an important role for cholesterol handling in the 
disease mechanism [14, 15]. 
APOE is located in the shell of lipoprotein par-
ticles, with hydrophobic substances including cho-
lesterol, which is loaded onto the lipoprotein parti-
cle by the enzyme ABCA1, being transported in the 
core [16]. The destination of the lipoprotein parti-
cles is determined by the receptors for the proteins 
on the surface of the lipoprotein shell. APOE, on the 
outer surface of the lipoprotein particles, binds to 
receptors of the low-density lipoprotein (LDL) recep-
tor family (principally LRP1/APOE receptor) present 
on neuronal cell membranes and, by this mecha-
nism, the cholesterol is internalised within the  
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neurons. Some CNS lipoprotein particles also bear 
APOJ (clusterin) on their surface; ependymal cells, 
but not neurons or other glia, bear APOJ receptors 
so it is unlikely to be relevant for cholesterol delivery 
to neurons [17]. However, it is notable that in ge-
nome-wide association studies, polymorphism of 
APOJ/clusterin gene has also been shown to influ-
ence risk for AD [18], raising the possible importance 
of clearance of lipoprotein particles and cholesterol 
to the CSF. 
Outside the brain, in the rest of the body, there 
are several other lipoproteins that can fulfil the 
function of cholesterol transport in addition to 
APOE, including APOA which is synthesised in the 
liver [19]. APOA-containing lipoprotein particles are 
detectable in the CSF but appear to be excluded 
from the brain parenchyma by the blood-brain bar-
rier. Consequently, the cholesterol required by neu-
rons is synthesised within the brain and delivered to 
neurons by APOE-containing lipoprotein particles 
[20] [9, 21]. 
Lipoprotein particles become en-
trapped in the ageing extracellular ma-
trix 
The lipoprotein particles, which resemble the 
high-density lipoproteins (HDL) present in the blood-
stream, are in the region of 11-20 nm in diameter 
[22]. In order to transport cholesterol to neurons, 
they have to travel in the extracellular space in the 
brain which itself measures only about 40 nm be-
tween adjacent cells [23], below the resolution of 
light microscopy. Small molecules can pass readily, 
by diffusion and potentially by active flow, through 
the extracellular space but diffusion even of conven-
tional macromolecules much smaller that lipopro-
tein particles is hindered, particularly in pathological 
processes such as gliosis (activation of glial cells) 
[24], which occurs in association with ageing and the 
neurodegeneration in AD. 
An additional complexity is that the extracellu-
lar space resembles a sponge, containing the extra-
cellular matrix (ECM). In the brain, the ECM is a com-
plex multimolecular three-dimensional structure 
consisting of proteoglycans/glycosaminoglycans, 
proteins, proteinases, and cytokines [25]. Expres-
sion of collagen IV, laminin and fibronectin is upreg-
ulated in the cerebral cortex in early AD. With age-
ing-related changes to the extracellular matrix, ex-
acerbated by other risk factors for AD (hypertension, 
diabetes, obesity, inflammation and physical inactiv-
ity), the narrow extracellular space likely becomes 
compromised (‘fibrosed’), impeding the movement 
of, and trapping, lipoprotein particles in between 
cells. 
Interestingly, oxidative modification of plasma 
lipoproteins is one of the earliest steps in the devel-
opment of atherosclerosis, involving accumulation 
of lipoprotein particles in the vessel wall provoking 
inflammatory reaction [26]. In AD patients, there is 
evidence of greater oxidation of plasma and CSF lip-
oproteins [26] and this could conceivably further im-
pair the passage of lipoprotein particles through the 
extracellular space in the brain. Consequently, the 
APOE-mediated system for transporting cholesterol 
and lipids from glial cells to neurons in the brain is 
unique, crucial for neuronal function and plasticity 
and vulnerable to age-related failure (Figure 1). It is 
proposed that this results in a number of conse-
quences leading to the key features of AD patho-
physiology as follows. 
Entrapment of lipoprotein particles 
can explain the key features of 
Alzheimer’s disease 
Aβ deposition 
In the parenchyma as plaques: 
Aβ peptide is notoriously insoluble in an aque-
ous environment, but it is lipid soluble and is trans-
ported in the hydrophobic core of lipoprotein parti-
cles [27-30]. Therefore, trapping lipoprotein parti-
cles would immobilise Aβ in the extracellular space. 
As the trapped particles degrade and rupture, we 
propose they release Aβ peptide into the surround-
ing aqueous environment where it aggregates, initi-
ating the formation of extracellular Aβ plaques. Co-
localisation of APOE with Aβ plaques is consistent 
with the origin of the Aβ as being from APOE-con-
taining lipoprotein particles [31]. Immunohisto- 
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Figure 1. Entrapment of lipoprotein particles 
in the brain causes Alzheimer’s disease. 
Lipoprotein particles transport cholesterol 
from glial cells, where it is synthesised, to 
neurons which require cholesterol for synap-
tic plasticity. The lipoprotein particles have a 
cholesterol-containing hydrophobic core, in 
which Aβ is solubilised, and a hydrophilic sur-
face containing apolipoprotein E. Receptors 
for APOE on the neuronal cell membrane de-
termine the destination of the particles. The 
lipoprotein particles must navigate the extra-
cellular space to reach the neurons, a narrow 
cleft barely wider than the particles them-
selves. As the extracellular matrix ages, lipo-
protein particles become trapped between 
cells and this primary abnormality results in 
reduced delivery of cholesterol to neurons 
leading to impaired synaptic plasticity, crucial 
for learning and memory. Impaired move-
ment of lipoprotein particles in the extracel-
lular space in the brain in ageing is central to 
and causes all the key pathophysiological fea-
tures of Alzheimer’s disease: degeneration of 
entrapped lipoprotein particles releases Aβ 
which aggregates in the aqueous environ-
ment of the extracellular space; a microglial 
reaction to the Aβ results in secretion of neu-
rotoxic substances; neuronal cholesterol defi-
ciency causes intraneuronal tau accumula-
tion. [Artwork by Dr Jennifer M Dewing] 
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chemistry for Aβ on semi-thin sections (1µm) shows 
that diffuse plaques, usually interpreted as the ear-
liest stage of Aβ deposition, are formed from a clus-
ter of dot-like structures [32], and electron micros-
copy shows small vesicles associated with amyloid 
fibrils in the extracellular space [32]. In the context 
of the current hypothesis, it is intriguing to speculate 
that these might be entrapped lipoprotein particles 
from which the amyloid has originated. 
APP transgenic mice, over-expressing the 
V717F human amyloid precursor protein, develop 
Aβ plaques as they age. Interestingly, when crossed 
with APOE knock out mice so that they lack APOE, 
these mice do not accumulate plaques [33]. This 
finding indicates that APOE is essential for the dep-
osition of Aβ plaques, supporting the mechanism we 
propose. 
With ageing, the primary risk factor for AD, the 
human brain decreases in weight and size with an 
overall decline in cortical cholesterol that acceler-
ates from the age of 80 [34, 35]. This is consistent 
with age-associated entrapment of the lipoprotein 
particles impairing delivery of cholesterol to neu-
rons and resulting in neuronal cholesterol deficiency 
[36]. This has further effects on Aβ as cholesterol de-
ficiency leads to thinning of the cell membrane, 
shifting the site for secretase cleavage of the amy-
loid protein precursor (APP) from producing pre-
dominantly the shorter form of Aβ (Aβ40) to the 
longer form (Aβ42) which is relatively even more in-
soluble and prone to aggregation [37, 38]. This exac-
erbates the effect of trapped lipoprotein particles as 
the Aβ42 then coalesces onto the initial plaque 
seeds facilitating their growth. 
In physiological conditions, Aβ is suggested to 
act as a regulator of cholesterol homeostasis as ob-
served in experimental models [39]. In humans, the 
familial forms of Alzheimer’s disease are due to an 
imbalance in Aβ production and are associated with 
increased cholesterol levels [40]. The binding of 
APOE to lipoprotein receptor-related protein (LRP) 
[41], the major APOE receptor on neurons, is also in-
volved in the cellular uptake of cholesterol and Aβ, 
consistent with APOE, cholesterol and Aβ all being 
components of the lipoprotein particle. 
In the blood vessel walls as cerebral amyloid angiop-
athy (CAA): 
Aβ also colocalises with APOE in the walls of 
cerebral blood vessels suggesting that lipoprotein 
particles become trapped in the extracellular space 
of the vessel wall basement membrane as a conse-
quence of age-related changes. The blood vessel 
dysfunction caused by the presence of CAA further 
compromises brain function by haemorrhage, is-
chaemia and paralysing autoregulation of cerebral 
blood flow [42]. 
Impaired neuronal and synaptic function 
Deficiency of neuronal cholesterol results in 
impaired communication between neurons at the 
synapse, and particularly it interferes with the alter-
ations in neurons which underpin learning and 
memory (i.e. synaptic plasticity) [43-46]. Synaptic 
plasticity requires neuronal cell membrane to be 
synthesised to form and re-form synapses as they 
are remodelled. In neuronal cultures, the presence 
of glial cells enhances the formation and function of 
synapses and the essential factor mediating this ef-
fect has been identified as glia-derived cholesterol, 
delivered to the neurons by APOE-containing lipo-
protein particles binding to the neuronal LDL recep-
tors [11, 47, 48].  
Interestingly, in a number of clinical studies of 
traumatic brain injury, the possession of APOE ε4 is 
associated with a worse outcome and severe neuro-
logic deficits [49-51]. This seems particularly so in 
young people in whom neuronal plasticity after in-
jury might otherwise be more pronounced [50]. Ex-
perimental studies in APOE ε4 transgenic mice con-
firmed impaired neuronal plasticity after brain injury 
[52-56]. Further evidence comes from experimental 
models of global cerebral ischaemia in which APOE-
deficient mice have increased neuronal damage 
which is ameliorated by intraventricular infusion of 
lipoprotein particles [57]. In addition, agonists of 
Liver X receptors (LXR), which act as cholesterol sen-
sors and promote lipidation of APOE by ATP-binding 
cassette transporter A1 (ABCA1), ameliorate neu-
ronal injury in experimental models of trauma [58] 
and reverse deficits in mouse models of AD [59]. 
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The effects of neuronal and synaptic dysfunc-
tion due to lack of cholesterol [60] would be ex-
pected to be most pronounced in neuroanatomical 
locations in which plasticity is greatest (i.e. hippo-
campus involved in memory, association cortex in-
volved in interpretation of sensations) and less se-
vere or absent where plasticity is least (i.e. primary 
motor and sensory cortex, cerebellum, spinal cord). 
This is consistent with the clinical observations that 
the hierarchical sequence of loss of functions over 
time in AD follows the distribution of neuroplasticity 
[61]. 
Tau protein accumulation 
We propose that neuronal cholesterol defi-
ciency, resulting from the entrapment of lipoprotein 
particles, leads to the intracellular aggregation of 
tau. Tau is involved in maintaining the cytoskeletal 
structure of neurons and, in particular, the transport 
of proteins from the cell body along axons to the 
synapses. Accumulation of hyperphosphorylated 
tau occurs early in regions where the cholesterol is 
most in demand, that is where the rate of plasticity 
and synaptic remodelling is greatest (i.e. hippocam-
pus, association cortex) and later or not at all where 
plasticity is least (i.e. primary motor and sensory cor-
tex, cerebellum, spinal cord). A difficulty in trying to 
explain a direct link between Aβ and tau pathology 
in AD has been that they appear to arise in different 
neuroanatomical locations; tau accumulation occurs 
earlier in the hippocampus and associated struc-
tures, only spreading later to the cerebral neocor-
tex, whereas Aβ accumulation occurs early in the 
cerebral neocortex. The hypothesis proposed here 
that there is not a direct link between Aβ and tau 
pathology, but rather that they are each driven by 
cholesterol deficiency, resolves this conundrum. 
Direct experimental support comes from cho-
lesterol depletion in neuronal cultures which in-
duces tau hyperphosphorylation that can be pre-
vented by treatment with lipoproteins and choles-
terol [62]. The link between neuronal cholesterol de-
ficiency and tau accumulation is further highlighted 
by the occurrence of tangles at a young age in Nie-
mann-Pick type disease type C, a rare progressive 
genetic disorder characterised by the inability of the 
body to transport cholesterol and lipids [63-64]. 
Additional circumstantial evidence supporting 
a link between cholesterol deficiency and tangle for-
mation potentially comes from the study of chronic 
traumatic encephalopathy (CTE). CTE is a condition 
caused by repeated blows to the head, typically in 
boxing and other sports, and is associated with the 
development of dementia with the formation of tan-
gles as the key pathological feature [65]. It has been 
found that after a head injury, levels of APOE and 
cholesterol-containing lipoproteins in the cerebro-
spinal fluid plummet, just at the time when there is 
an increased demand for cholesterol for neuronal 
repair [66-68]. This relative deficiency of choles-
terol, when recurrent over time with repeated 
blows to the head, could explain the development of 
tangles in CTE [51-56] [65]  
Studies using cerebral organoids derived from 
AD patients highlight an association of tau pathology 
with APOE ε4 carriage [69]. 
Glial cell dysfunction 
Astrocytes and microglia have a major role in 
supporting neurons and activation of glial cells is a 
hallmark of AD. In particular, they play an important 
role in the cycling of lipoprotein particles, scaveng-
ing lipid debris from degenerating neuron/synapses, 
lipidation the particles and releasing them for 
transport and uptake by neurons [70]. In APOE ε4 
carriers, the brain is relatively deficient in APOE and 
the lipoprotein particles are smaller [71], more 
prone to aggregate and carry less cholesterol, ren-
dering them particularly vulnerable to the effects of 
age-related cholesterol deficiency. Human induced 
pluripotent cell (iPSC)-derived astrocytes from ε4 
homozygotes produce lipoprotein particles that are 
smaller, carry less cholesterol and support neurons 
less well in terms of viability and expression of syn-
aptic proteins compared with those from ε3 carriers 
[72]. 
Microglia are the immune cells of the brain and 
are markedly activated in AD [73, 74]. Many of the 
genes identified in genome-wide association studies 
are expressed by microglia, indicating that they play 
an important role in the development and/or pro-
gression of the disease [75]. The presence of extra-
cellular Aβ expelled by trapped and degraded lipo-
Free Neuropathology 2:30 (2021) Boche et al 





protein particles is putatively recognised by the mi-
croglial pattern recognition receptors (PPRs) 
evolved to detect molecular patterns associated 
with the bacterial cell walls. The consequent pro-in-
flammatory state provoked by this response causes 
release of cytotoxic substance evolved to destroy in-
vading micro-organisms, which inadvertently has a 
harmful effect on neurons, compounding the effects 
of cholesterol deficiency [73, 76]. 
Weaknesses/limitations of the hypothesis 
The ideas presented here form a hypothesis to 
explain the development of AD which is coherent 
and explains many facets of the disease. It is im-
portant to emphasise that a hypothesis is also an ex-
trapolation of what is currently known and so some 
of the statements above are not firmly established 
but are potentially controversial and remain to be 
explored in the testing of the hypothesis. Potential 
thorns in the side of this hypothesis include: 
 Localisation of Aβ within APOE-containing lipo-
protein particles has not been directly demon-
strated in the human brain. This needs to be ex-
plored and represents an important gap in our 
knowledge. Available technology is a limitation 
because the lipoprotein particles are below the 
resolution of light/confocal microscopy but are 
potentially amenable to study by novel 3D elec-
tron microscopy methods combined with mul-
tilabel immunostaining. 
 Direct evidence that lipoprotein particles be-
come trapped in the extracellular space, disin-
tegrate and release Aβ is currently lacking. 
 Studies of immunohistochemistry for Aβ and 
APOE identify APOE in some, but not all 
plaques. APOE seems to be present particularly 
in cored plaques, which are interpreted as later 
stage plaques, rather than early diffuse plaques 
as might be predicted from the hypothesis. The 
presence of APOE in later stage plaques could 
possibly reflect involvement of APOE-contain-
ing lipoprotein particles in attempted removal 
of Aβ, in addition to a role in plaque formation. 
 Evidence that high peripheral cholesterol levels 
are associated with increased risk of AD and 
that statins, which reduce circulating choles-
terol by inhibiting the cholesterol-synthesising 
enzyme HMG-CoA reductase, may reduce risk 
for AD [77] might seem to contradict the hy-
pothesis presented here. It seems that statins 
do reduce cholesterol levels in the brain [78]. 
However, it may be that the relative amounts 
of cholesterol, Aβ and APOE are important i.e., 
that there is sufficient cholesterol as required 
by neurons, sufficient APOE to solubilise the 
cholesterol and a sufficient volume of lipophilic 
core within the lipoprotein particles to 
transport Aβ and prevent its escape into the 
aqueous environment of the extracellular 
space where it is prone to aggregate. 
Therapeutic consequences 
Over the past decades, human clinical trials of 
new therapies for AD have been unrelentingly disap-
pointing. This is despite there being no shortage of 
endeavour and expenditure, and no lack of success-
ful therapeutic studies in animal models of specific 
aspects of AD. Why is this? We suggest it is because 
the wrong targets have been addressed. Whereas 
each of the major suspects listed above (Aβ, tau, 
glial cells) may exacerbate the neurodegeneration 
and set up self-perpetuating vicious cycles, we pro-
pose they are not the initiating factor in sporadic AD, 
either singly or in combination. The pathophysiolog-
ical scheme outlined above indicates that, according 
to this hypothesis, Aβ and tau are not the cause of 
AD but are a consequence of the primary abnormal-
ity, which is trapping of lipoprotein particles in the 
extracellular space resulting in disruption of the nor-
mal system of delivery of cholesterol to neurons. 
This implies that even if, for example, the AD brain 
can be completely cleared of Aβ plaques, this will 
not halt the neurodegenerative decline as observed 
first in the long-term follow up of AD patients im-
munised against Aβ using AN1792 [79] and also in 
subsequent trials. Instead, therapy for AD must be 
directed at the health of the extracellular space, 
cholesterol and APOE, lubricating the passage of 
cholesterol-containing lipoprotein particles. 
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